Arcus Biosciences (RCUS) EBIT Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 12.69% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 75.16% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -347.04% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 80.62% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 1.27% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 8.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,386.07% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -9.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.84% |
| Dec 31, 2025 | -10.68% |
| Sep 30, 2025 | -35.24% |
| Jun 30, 2025 | 92.45% |
| Mar 31, 2025 | -662.50% |
| Dec 31, 2024 | -13.19% |
| Sep 30, 2024 | -31.25% |
| Jun 30, 2024 | -27.71% |
| Mar 31, 2024 | 81.40% |
| Dec 31, 2023 | -22.97% |
| Sep 30, 2023 | -14.29% |
| Jun 30, 2023 | -20.29% |
| Mar 31, 2023 | -28.36% |
| Dec 31, 2022 | -126.33% |
| Sep 30, 2022 | 10.41% |
| Jun 30, 2022 | 9.37% |
| Mar 31, 2022 | 7.90% |
| Dec 31, 2021 | 642.75% |
| Sep 30, 2021 | -5,134.54% |
| Jun 30, 2021 | -67.79% |
| Mar 31, 2021 | -156.15% |
| Dec 31, 2020 | -195.41% |
| Sep 30, 2020 | 106.68% |
| Jun 30, 2020 | -55.61% |
| Mar 31, 2020 | -51.28% |
| Dec 31, 2019 | -29.98% |
| Sep 30, 2019 | -91.43% |
| Jun 30, 2019 | -83.41% |
| Mar 31, 2019 | -40.82% |
| Dec 31, 2018 | -1.05% |
| Sep 30, 2018 | 47.50% |
| Jun 30, 2018 | -64.52% |
| Mar 31, 2018 | -82.62% |